R2 Technologies Receives Final Tranche of $30M Investment to Launch Revolutionary Glacial Rx™ and Glacial Spa™ Aesthetic Skin Treatments
R2 Technologies Receives Final Tranche of $30M Investment to Launch Revolutionary Glacial Rx™ and Glacial Spa™ Aesthetic Skin Treatments News provided by Share this article Share this article SAN RAMON, Calif., Feb. 3, 2021 /PRNewswire/ -- R2 Technologies Inc. ("R2") has received $10 million in funding from Huadong Medicine Company Limited ("Huadong") as the third and final tranche of Huadong's $30 million Series B equity investment. R2's post-money valuation is $113 million which is a predetermined valuation established at the time of the Company's Series B close in June 2019. The funds...
Source: prnewswire.com